Cardiovascular Risk

Cardiovascular·MeSH: Renal Insufficiency, Chronic

14 drugs in development·11 companies·6 clinical trials

Drug Pipeline by Phase

Approved(10)

Drug	Company
exforge hct	Novartis AG (NVS)
felodipine	Mylan II B.V. (MYL)
losartan	Teva Pharmaceutical Industries Limited (TEVA)
nebivolol	ANI PHARMACEUTICALS INC (ANIP)
olmesartan medoxomil	Amneal Pharmaceuticals, Inc. (AMRX)
telmisartan	Inventiva S.A. (IVA)
Trulicity	ELI LILLY & Co (LLY)
Trulicity®	ELI LILLY & Co (LLY)
vascepa	AMARIN CORP PLCUK (AMRN)
vascepa	AMARIN CORP PLCUK (AMRN)

Phase 3(1)

Drug	Company
Zilebesiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Phase 1(3)

BioSniper tracks 14 drugs in development for Cardiovascular Risk across 11 companies.

There are 6 clinical trials targeting Cardiovascular Risk tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.